Dyronib 50 Tablets (Dasatinib Tablets 50 mg)

Dyronib 50 Tablets is a branded oncology oral formulation containing dasatinib, a tyrosine kinase inhibitor used within regulated cancer treatment frameworks. Manufactured to meet international pharmaceutical quality standards, Dyronib 50 Tablets are intended for professional distribution through licensed and regulated supply channels. AmeriDrugs supplies this product exclusively for export to authorized importers, distributors, hospitals, and pharmacies serving oncology-focused healthcare systems.

Active Ingredient (API + Strength)

• Active Pharmaceutical Ingredient: Dasatinib

• Strength: 50 mg per tablet

• Dosage Form: Film-coated tablet

Therapeutic Use (Informational, Non-Advisory)
Dasatinib is classified as a tyrosine kinase inhibitor and is utilized in approved oncology treatment protocols for specific hematological malignancies, including certain leukemias, as defined by regulatory authorities. Dyronib 50 Tablets are supplied for use strictly in accordance with locally approved clinical guidelines. This information is provided for product identification and regulatory clarity only and does not constitute medical advice or treatment recommendations.

Dosage Form & Route of Administration

• Dosage Form: Oral solid dosage (tablet)

• Route of Administration: Oral

• Prescription Status: Prescription-only medicine

• Intended for dispensing through regulated pharmaceutical and healthcare channels

Quality & Manufacturing Standards
Dyronib 50 Tablets are manufactured in accordance with current Good Manufacturing Practices (GMP) and applicable pharmacopeial standards. Production processes include validated controls to ensure tablet uniformity, stability, and batch consistency. Each batch is subjected to comprehensive quality testing aligned with international regulatory and export requirements.

Packaging Information (Export-Oriented)

• Primary Packaging: Blister strips

• Pack Size: 60 tablets per box

• Secondary Packaging: Printed carton with regulatory-compliant labeling

• Packaging designed for secure international pharmaceutical logistics

Target Buyers

• Licensed pharmaceutical importers and distributors

• Oncology hospitals and specialty treatment centers

• Retail and wholesale pharmacies operating under prescription regulations

• Government and private healthcare procurement agencies

• International distributors specializing in oncology oral formulations

Regulatory & Compliance Note
Dyronib 50 Tablets is a prescription-only oncology medicine intended for regulated pharmaceutical distribution. Not for direct consumer self-use. Supply is subject to import authorization, local drug regulatory approvals, and applicable healthcare compliance requirements in the destination country. AmeriDrugs adheres to global export compliance standards and supports required regulatory documentation.